Intercalated treatment of advanced non-small cell lung cancer patients with gradual progression after failure of EGFR tyrosine kinase inhibitors therapy：a clinical observation
ZHONG Yuejiao
LIU Min
MA Rong
SUN Xiaofeng
WU Pingping
ZHOU Qin
ZHU Huayun
CHEN Jia
CHEN Lingxiang
Abstract：Objective To observe the PFS (Progression Free Survival) could be extended in advanced NSCLC(non-small cell lung cancer) patients with gradual progression after failure of EGFR tyrosine kinase in-hibitors therapy by intercalated treatment. Methods 24 advanced NSCLC patients from August 2009 to Decem-ber 2014 were collected after gradual progression treated by EGFR-TKIs. All of these patients were accepted in-tercalated treatment of chemotherapy and EGFR-TKIs, in comparison with the PFS of EGFR TKIs treatment to the gradual progression and the PFS of EGFR TKIs treatment to progression of intercalated treatment. Follow-up visit came to end on April 30th , 2015, the median PFS survival was draun accordingly. Results 22 patients could be evaluated on the basis of PFS. The PFS of EGFR TKIs treatment to the gradual progression was 13. 3 months. The PFS of EGFR TKIs treatment to progression of intercalated treatment was 24 months (P < 0. 001). Conclusion The PFS could be signally extended in NSCLC patients with gradual progression after failure of EGFR tyrosine kinase inhibitors therapy by intercalated treatment.
Keywords：EGFR-TKIsNSCLC gradual progressionIntercalated treatmentNSCLCChemothenapyPFS
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 364-367 )